Speaker: Maureen Cronin, Ph.D., Executive Director, Strategic Information Management, Celgene Corporation
Personalized Medicine’ initially focused on single or minimal sets of biomarkers to identify patient responders to specific drug therapies. Identifying EGFR mutation profiles for TKIs, BRAF V600E mutations for vemurafenib or EML4-ALK translocation for cizotinib were heralded as major advances in tailored therapy. In reality, emerging science tells us these are exceptions, not the rule. This session will focus on building comprehensive molecular models of disease and exploring how mapping models of drug activity onto these models may give sustainable impetus to precision medicine. Effective therapeutic management will require understanding the patient status with respect to disease context.
Loading more stuff…
Hmm…it looks like things are taking a while to load. Try again?